Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
FiercePharma18h
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Wall Street Is Selling ETFs That Mimic the Private Equity Boom
Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...